Scancell Holdings Plc Immuno-Oncology Summit Europe 2017
March 20 2017 - 2:01AM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
20 March 2017
20 March 2017
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell to present at the Immuno-Oncology Summit Europe
2017
Professor Lindy Durrant, Scancell's CSO, to chair and present in
a session entitled:
"Combining Checkpoint Inhibitors with Other Modalities"
Scancell Holdings plc, ('Scancell' or the 'Company') the
developer of novel immunotherapies for the treatment of cancer,
announces that it will be participating in the upcoming Inaugural
Combination Immunotherapy meeting, part of the Second Annual
Immuno-Oncology Summit Europe 2017, 20-24 March 2017 at the Hilton
Canary Wharf, London, UK, alongside other industry leaders from
Merck, Sharp and Dohme, Bristol-Myers Squibb and Cancer Research
UK.
Prof. Lindy Durrant, Ph.D., Chief Scientific Officer of Scancell
and Professor of Cancer Immunotherapy, University of Nottingham,
will chair the session entitled: "Combining Checkpoint Inhibitors
with Other Modalities" on Thursday 23 March 2017. Prof. Durrant is
also featured as a presenter in this session and will deliver a
presentation entitled: "Combinations of Novel Vaccines with
Checkpoint Inhibitors", scheduled to take place at 14.20 GMT.
During the presentation, Prof. Durrant will discuss progress
made with Scancell's two cancer immunotherapy platforms,
ImmunoBody(R) and Moditope(R).
ImmunoBody(R) utilises both cross- and direct-presentation to
increase T-cell avidity by 100 fold. In Phase 1/2 trials, it
induced T-cell responses, tumour regression and long term survival.
In combination with checkpoint inhibitors, it induced 100% tumour
regression in established models. Phase 2 trials of ImmunoBody(R)
vaccines in combination with checkpoint inhibitors in melanoma and
non-small cell lung cancer are being planned.
Moditope(R) stimulates powerful anti-tumour T-cell responses
against neo-epitopes produced by enzymes induced by cellular
stress. First-in-man clinical studies for breast cancer, ovarian
cancer and osteosarcoma are anticipated to commence in 2018.
For Further Information:
Dr John Chiplin, Executive
Chairman +1 858 900 2646
Dr Richard Goodfellow, Scancell Holdings +44 (0) 20 3727
CEO Plc 1000
Freddy Crossley (Corporate +44 (0) 20 7886
Finance) 2500
Tom Salvesen (Corporate Panmure Gordon +44 (0) 20 7886
Broking) & Co 2500
+44 (0) 20 3727
Mo Noonan/Simon Conway FTI Consulting 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
Scancell's first ImmunoBody(R), SCIB1 is being developed for the
treatment of melanoma. Data from the Phase 1/2 clinical trial
demonstrate that SCIB1, when used as monotherapy, has a marked
effect on tumour load, produces a melanoma-specific immune response
and highly encouraging survival trend without serious side effects.
In patients with resected disease there is increasing evidence to
suggest that SCIB1 may delay or prevent disease recurrence.
Scancell's ImmunoBody(R) vaccines target dendritic cells and
stimulate both parts of the cellular immune system: the helper cell
system where inflammation is stimulated at the tumour site and the
cytotoxic T-lymphocyte or CTL response where immune system cells
are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and
checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune
checkpoint pathways) have shown enhanced tumour destruction and
significantly longer survival times than when either treatment was
used alone. Experimental data suggests that the high avidity T
cells induced by ImmunoBody(R) vaccines increase expression of
PDL-1 on the tumour cell surface, thereby making the tumours more
sensitive to checkpoint inhibitor drugs. Re-challenging animals
with tumour cells after SCIB1 treatment resulted in 100% survival
suggesting that ImmunoBody(R) induces a powerful memory response.
Such an effect has not been observed with checkpoint
inhibitors.
Scancell has also identified and patented a series of modified
epitopes that stimulate the production of killer CD4+ T cells that
destroy tumours without toxicity. The Directors believe that the
Moditope(R) platform could play a major role in the development of
safe and effective cancer immunotherapies in the future.
About Immuno-Oncology Summit Europe 2017
Following the success of our inaugural Cancer Biotherapeutics
conference in London, we are pleased to announce the
Immuno-Oncology Summit Europe 2017, to be held 20-24 March in the
heart of London's Canary Wharf Business District.
With an expanded three-track program, attendees can now
experience a full week of cutting-edge science and discussion. The
first track on Novel Approaches for Cancer focuses on advances in
T-cell technology including next-generation CAR Ts, TCRs, and TILs.
In addition it covers bispecifics: for T and NK cell engagement; in
the clinic; and modelling for optimal affinity. The track also
presents genetic engineering technologies for T cells, preclinical
models, and production strategies, and focuses on specificity,
off-target tox, and safety. The second track on Immunomodulatory
Approaches will present advances with checkpoint inhibitors,
agonistic receptor engagement, NK and macrophage activation,
Fc-engineering technologies, and cytokine-based therapies, and
address the challenge of tumours unresponsive to checkpoint
blockade. It includes a keynote session on current understanding of
the role of the immune system in cancer. Combination Immunotherapy
will review the strategies and clinical trials for designing
rational combination immunotherapies, provide case studies of
immune modulator combinations, as well as combinations of
checkpoint inhibitors with other modalities, and discuss biomarker-
and mechanism-based selection of IO combinations.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGMFLLLGNZM
(END) Dow Jones Newswires
March 20, 2017 03:01 ET (07:01 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024